What's Happening?
Stimvia, a Czech medtech company, has completed a clinical study on its URIS device, which aims to treat symptoms of Parkinson’s disease. The study, published in Clinical Parkinsonism & Related Disorders, highlights the device's safety and positive impact on symptom relief and quality of life for patients. The URIS device uses peroneal electrical transcutaneous neuromodulation to address motor dysfunction and other symptoms associated with Parkinson’s. The study involved 12 patients who used the device daily for six weeks, showing improvements in motor symptoms and daily comfort.
AD
Why It's Important?
The URIS device offers a non-invasive alternative to deep brain stimulation, potentially transforming treatment options for Parkinson’s disease. With over 10 million people affected worldwide, advancements in non-invasive treatments could significantly improve patient outcomes and quality of life. The device's ability to enhance daily functioning without severe side effects presents a promising option for early-stage Parkinson’s patients. This development could lead to broader acceptance and integration of neuromodulation therapies in standard treatment protocols.
What's Next?
Stimvia plans to conduct a larger international clinical trial to further validate the URIS device's effectiveness. The trial is expected to launch this fall, with contributions from experts across Europe. The company aims to expand its research and development efforts, potentially leading to wider adoption of the URIS device in clinical settings. Continued success in trials could pave the way for regulatory approvals and commercialization, offering new hope for Parkinson’s patients globally.
